多发性骨髓瘤治疗策略进展  

Treatment strategy of multiple myeloma in 2011

作　　者：Michel Delforge(口述) 庄俊玲(编译)[2] 

机构地区：[1]University Hospital Leuven,Leuven Belgium [2]北京协和医院血液内科,北京100730

出　　处：《中国实用内科杂志》2012年第3期163-166,共4页Chinese Journal of Practical Internal Medicine

摘　　要：多发性骨髓瘤仍是一种不可治愈的血液肿瘤,近10年的治疗突破很大程度上依赖新药的研发,主要包括蛋白酶体抑制剂硼替佐米、免疫调节剂如来那度胺和沙利度胺等。力求达到完全缓解(CR)是目前的治疗目标,因为CR意味着无进展生存期(PFS)甚至总生存期(OS)的延长。以新药为基础的不同诱导方案显著提高一线治疗缓解率。缓解后或移植后进行巩固和维持治疗显著延长PFS。文章主要对包含新药的诱导方案进行总结,并简要讨论难治复发骨髓瘤患者的治疗。Summary：Muhiple myeloma is an incurable hematological malignancy. A revolution in last decade in myeloma treatment has taken place due to the development of new agents, including proteasome inhibitor bortezomib, imunomodulatory drugs such as lenalidomide and thalidomide. The current treatment goal is to achieve complete response （CR） because CR can be translated into significantly prolonged progression free survival （PFS） even overall survival （OS）. New drug based front- line regimens significantly improve response rate.Consolidation and maintenance regimens prolong PFS. In this article,new drug based regimens as induction and for relapsed patients are summarized.

关 键 词：多发性骨髓瘤 硼替佐米 沙利度胺 来那度胺 

分 类 号：R733.3[医药卫生—肿瘤]